The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

Fernandez-Gomez, Jesus; Madero, Rosário; Solsona, E.; Unda, Miguel; Martínez‐Piñeiro, Luis; Ojea, A; Portillo, J.A.; Montesinos, M.; Gonzalez, M. S.; Pertusa, C; Rodríguez‐Molina, Jesús; Camacho, José Emilio; Rabadán, M; Astobieta, Ander; Isorna, Santiago; Muntañola, Pedro; Gimeno, A.; Blas, Miguel; Martínez-Piñeiro, J A

doi:10.1016/j.eururo.2011.05.033

Cited by 152 publications

(71 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also consistent with observations from previous studies that the EORTC table overestimated the risk of recurrence and progression in high-risk patients undergoing BCG instillation therapy. 7 Considering that the EORTC model could stratify Chinese patients (where BCG instillation therapy was not available) to a better degree, 9,11 the patient cohort seems to be crucial to determining which scoring system is more applicable.…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6][7][8][9] Among them, the CUETO group validated the EORTC table using a dataset from the CUETO scoring system. 7 Their results showed that the EORTC tables overestimated the risk of recurrence in all risk groups, as well as the probabilities of progression in higher-risk patients. This observation is consistent with the notion that BCG is superior to chemotherapy in terms of preventing recurrence and progression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non‐muscle invasive bladder cancer treated with bacillus Calmette–Guérin

et al. 2014

View full text Add to dashboard Cite

Abbreviations & AcronymsObjective: To validate two prediction models (European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment) for recurrence and progression of non-muscle invasive bladder cancer in Japanese patients who underwent bacillus Calmette-Guérin instillation therapy. Methods: From March 1985 to April 2007, data were analyzed from 366 patients who underwent transurethral resection of bladder tumor followed by bacillus Calmette-Guérin instillation therapy. The ability of two scoring models to predict recurrence and progression was assessed by concordance index. Results: For recurrence probability, the concordance index of the European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment models was 0.514 and 0.576, respectively, which was lower than that (0.604) of a selected single prognostic factor (age) by our multivariate analysis. For progression probability, the concordance index of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment models was 0.693 and 0.764, respectively, which was higher than that (0.633) of a selected single factor (T stage) by our multivariate analysis. The Spanish Urological Club for Oncological Treatment scoring system resulted in better stratification of tumor recurrence and progression when compared with the European Organization for Research and Treatment of Cancer model, probably because more patients underwent bacillus Calmette-Guérin treatment in the Spanish Urological Club for Oncological Treatment cohort than in the European Organization for Research and Treatment of Cancer cohort. Conclusions: The Spanish Urological Club for Oncological Treatment scoring system is a good predictor of tumor recurrence and progression in Japanese patients who underwent bacillus Calmette-Guérin immunotherapy. A large prospective study is warranted to confirm the efficacy of this system.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non‐muscle invasive bladder cancer treated with bacillus Calmette–Guérin

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Otros estudios han demostrado por otro lado las limitaciones en los modelos pronósticos de mayor impacto como el de la EORTC [1] y del CUETO [6] . En una análisis para identificar la fiabilidad de ambos modelos sobre 4689 pacientes se detecta que ambos modelos presentan una pobre discriminación tanto para la recidiva como para la progresión sobrestimando los riesgos [25].…”

Section: Discussionunclassified

Cálculo del riesgo biológico de multirrecidiva y progresión del carcinoma urotelial no músculo-invasivo mediante nuevos modelos matemáticos

Marco

Santamaría

Pontones

et al. 2014

Actas Urológicas Españolas

View full text Add to dashboard Cite

show abstract

“…Для каждой группы построены графики и рассчитаны показатели 1-и 5-летнего кумулятивного риска реци-дивирования и прогрессирования и их 95 % довери-тельные интервалы (ДИ). 173 (18,8) 160 (17,4) 192 (20,9) 184 (20,0) …”

Section: Introductionunclassified

Assessment of recurrence and progression risk in patients with non-muscle invasive bladder cancer

Rolevich¹,

Mirilenko²

2016

Cancer Urology

View full text Add to dashboard Cite

show abstract

The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

Cited by 152 publications

References 21 publications

External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non‐muscle invasive bladder cancer treated with bacillus Calmette–Guérin

External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non‐muscle invasive bladder cancer treated with bacillus Calmette–Guérin

Cálculo del riesgo biológico de multirrecidiva y progresión del carcinoma urotelial no músculo-invasivo mediante nuevos modelos matemáticos

Assessment of recurrence and progression risk in patients with non-muscle invasive bladder cancer

Contact Info

Product

Resources

About